GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (NAS:ALNY) » Definitions » Equity-to-Asset

Alnylam Pharmaceuticals (Alnylam Pharmaceuticals) Equity-to-Asset

: -0.06 (As of Dec. 2023)
View and export this data going back to 2004. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Alnylam Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-221 Mil. Alnylam Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $3,830 Mil. Therefore, Alnylam Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.06.

The historical rank and industry rank for Alnylam Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

ALNY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.06   Med: 0.67   Max: 0.91
Current: -0.06

During the past 13 years, the highest Equity to Asset Ratio of Alnylam Pharmaceuticals was 0.91. The lowest was -0.06. And the median was 0.67.

ALNY's Equity-to-Asset is ranked worse than
84.87% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs ALNY: -0.06

Alnylam Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Alnylam Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => 0.60 [6] => 0.30 [7] => 0.16 [8] => -0.05 [9] => -0.06 )
Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.30 0.16 -0.05 -0.06

Alnylam Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.08 -0.12 -0.04 -0.06

Competitive Comparison

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Equity-to-Asset falls into.



Alnylam Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Alnylam Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-220.644/3829.88
=-0.06

Alnylam Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-220.644/3829.88
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alnylam Pharmaceuticals  (NAS:ALNY) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Alnylam Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals (Alnylam Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Executives
Michael W Bonney director 65 HAYDEN AVE, LEXINGTON MA 02421
Pushkal Garg officer: CMO & EVP Dev & Med Affairs C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Akshay Vaishnaw officer: SVP, Clinical Research 300 THIRD STREET, CAMBRIDGE MA 02139
Yvonne Greenstreet officer: EVP, Chief Commercial Officer PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Jeffrey V. Poulton officer: Chief Financial Officer 300 THIRD STREET, CAMBRIDGE MA 02142
Tolga Tanguler officer: EVP, Chief Commercial Officer 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE MA 02142
Indrani Lall Franchini officer: EVP, CLO & Secretary C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Peter N Kellogg director MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Carolyn R Bertozzi director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Dennis A Ausiello director PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Charles Elliott Sigal director 32 BREARLY ROAD, PRINCETON NJ 08540
Phillip A Sharp director BIOGEN INC LEGAL DEPARTMENT, 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Maraganore director, officer: President and CEO 75 SIDNEY ST, CAMBRIDGE MA 02139
Laurie Keating officer: SVP,GC & Secretary 300 THIRD STREET, CAMBRIDGE MA 02142
Steven M Paul director C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285